TT223 + metformin

TT223 + metformin is a combination therapy under investigation for the treatment of type 2 diabetes. Metformin is a well-established oral antihyperglycemic agent in the biguanide class that lowers blood glucose by decreasing hepatic glucose production, reducing intestinal absorption of glucose, and improving insulin sensitivity through increased peripheral uptake and utilization. It does not increase insulin secretion but enhances the body's response to endogenous insulin[1][4][5]. TT223 is presumed to be an investigational compound; however, no detailed public information about its mechanism or developer was found in the provided sources.

Other names

biguanide (for metformin)